Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elvira Munteis

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
Medicina Clinica|February 10, 2015
[Muscle involvement in sickle cell disease]Miguel Ángel Rubio, Laura Díez, Nuria Álvarez, et al.
Annals of Thoracic Medicine|August 12, 2016
Pulmonary eosinophilia associated to treatment with natalizumabElena Curto, Elvira Munteis-Olivas, Eva Balcells, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|September 23, 2025
The Present and Future of Monoclonal Antibody Therapies for Multiple SclerosisSilvia Susin-Calle, Elvira Munteis, Pablo Villoslada, et al.
Journal of Neurology|May 27, 2011
Adult onset Pompe disease associated with multiple sclerosisMaria Sepulveda, Elvira Munteis, Miguel A Rubio, et al.
Expert Opinion on Investigational Drugs|February 25, 2025
Ongoing phase 2 agents for multiple sclerosis: could we break the phase 3 trial deadlock?Silvia Susin-Calle, Jose Enrique Martinez-Rodriguez, Elvira Munteis, et al.
Medicina Clinica|December 6, 2005
[Multiple sclerosis after treatment with anti-TNF-alpha antibodies]Elvira Munteis-Olivas, Carolina Pérez-García, Jaume Roquer-González, et al.
Revista De Neurologia|February 27, 2016
[Protocol for neurophysiological studies of the pelvic floor to appraise anorectal dysfunction in patients with multiple sclerosis]Ion Álvarez-Guerrico, Inmaculada Royo, Montserrat Andreu, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 20, 2003
Unconventional therapy in multiple sclerosisJaume Sastre-Garriga, Elvira Munteis, Jordi Río, et al.
Journal of Neurology|March 2, 2005
Previous antiplatelet therapy is an independent predictor of 30-day mortality after spontaneous supratentorial intracerebral hemorrhageJaume Roquer, Ana Rodríguez Campello, Meritxell Gomis, et al.
Medicina Clinica|March 3, 2009
[Lipid profile evolution during the first year of treatment with beta interferon in multiple sclerosis]Elisa Cuadrado-Godia, Elvira Munteis, José Enrique Martínez-Rodríguez, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
Medicina Clinica|February 10, 2015
[Muscle involvement in sickle cell disease]Miguel Ángel Rubio, Laura Díez, Nuria Álvarez, et al.
Annals of Thoracic Medicine|August 12, 2016
Pulmonary eosinophilia associated to treatment with natalizumabElena Curto, Elvira Munteis-Olivas, Eva Balcells, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|September 23, 2025
The Present and Future of Monoclonal Antibody Therapies for Multiple SclerosisSilvia Susin-Calle, Elvira Munteis, Pablo Villoslada, et al.
Journal of Neurology|May 27, 2011
Adult onset Pompe disease associated with multiple sclerosisMaria Sepulveda, Elvira Munteis, Miguel A Rubio, et al.
Expert Opinion on Investigational Drugs|February 25, 2025
Ongoing phase 2 agents for multiple sclerosis: could we break the phase 3 trial deadlock?Silvia Susin-Calle, Jose Enrique Martinez-Rodriguez, Elvira Munteis, et al.
Medicina Clinica|December 6, 2005
[Multiple sclerosis after treatment with anti-TNF-alpha antibodies]Elvira Munteis-Olivas, Carolina Pérez-García, Jaume Roquer-González, et al.
Revista De Neurologia|February 27, 2016
[Protocol for neurophysiological studies of the pelvic floor to appraise anorectal dysfunction in patients with multiple sclerosis]Ion Álvarez-Guerrico, Inmaculada Royo, Montserrat Andreu, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 20, 2003
Unconventional therapy in multiple sclerosisJaume Sastre-Garriga, Elvira Munteis, Jordi Río, et al.
Journal of Neurology|March 2, 2005
Previous antiplatelet therapy is an independent predictor of 30-day mortality after spontaneous supratentorial intracerebral hemorrhageJaume Roquer, Ana Rodríguez Campello, Meritxell Gomis, et al.
Medicina Clinica|March 3, 2009
[Lipid profile evolution during the first year of treatment with beta interferon in multiple sclerosis]Elisa Cuadrado-Godia, Elvira Munteis, José Enrique Martínez-Rodríguez, et al.
Pageof 3